The University of California, Irvine is enrolling patients in a new clinical trial for patients with COVID-19. The new treatment is a stem cell-derived natural killer cell therapy developed by Fordham Park, N.J.-based Celularity Inc. Celularity’s CYNK-001 therapy has a range of properties that “destroy virus-infected cells” and “coordinate a robust immune response that may lead to an effective and durable defense against the viral infection,” according to Celularity Chief Scientific Officer Xiaokui Zhang.
Startups & Innovations – R&D
Orange County Business Journal, Aug. 17, 2020
August 17, 2020